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Background: Metacognitive therapy (MCT) is an innovative treatment model addressing 
patterns of negative thinking seen in emotional disorders.   Unlike cognitive behaviour 
therapy (CBT), MCT has strategies targeting dysfunctional cognitive and metacognitive 
processes underlying perseverative thinking patterns and attentional biases. The aim of this 
pilot study was to compare changes in neuropsychological functioning related to executive 
function and attention in outpatients with depression following treatment with MCT or CBT. 
Methods: 48 participants referred for outpatient treatment of depression were randomised to 
12 weeks of MCT (n=23) or CBT (n=25). Mood severity and neuropsychological functioning 
were assessed at pre-treatment, 4 weeks and at end treatment (12 weeks).  
Results: There were no significant group differences at pre-treatment or 4 weeks on any 
neuropsychological test, although overall both groups showed a small improvement by 4 
weeks.  At end treatment, the MCT group demonstrated significantly greater improvement in 
performance on a task requiring spatial working memory and attention than the CBT group. 
Changes in executive functioning and attention were independent of change in mood 
symptoms. Conclusions: MCT may have an advantage over CBT in improving aspects of 
executive function, including attention. MCT’s emphasis on attentional training and flexible 
control of thinking may have a beneficial effect on neuropsychological functioning, 







Major depressive disorder (MDD) is characterised by significant neuropsychological 
impairment, with deficits being pronounced in executive function processes and attention. 
Executive function involves the regulation of cognitive activity encompassing capacities such 
as planning, reasoning, information updating and monitoring, working memory, and mental 





Although the relation between mood and neuropsychological symptoms in 
MDD is complex, the consensus is that in a substantial proportion of patients, a significant 
degree of neuropsychological impairment remains even after mood symptoms measured by 
mood rating scales have improved.
3, 4
 
Neuropsychological deficit has also been closely linked to functional outcomes in 
mood disorders
5
 and this may be a factor associated with poorer treatment outcomes
6
 and an 
increased likelihood of future relapse.
7
 Therefore, integrating specific cognitive remediation 
strategies to directly target executive function and attention deficits may be particularly 
important when treating mood disorders. 
Cognitive Behaviour Therapy (CBT) has demonstrated efficacy, is recommended in 
treatment guidelines and often referred to as the ‘gold standard’ of psychotherapies for 
depression (e.g.
8
). Despite this, only around half of patients respond to treatment and relapse 
is common
9
. The primary goal of CBT is to challenge the content of negative thoughts 
believed to be maintaining depressive affect.
10
  CBT does not specifically target the executive 
function and attention deficits which are increasingly recognised as playing a role in the 
aetiology and recurrence of depression (e.g.
11
). 
Metacognitive Therapy (MCT) is a relatively new psychotherapy focussing on altering 




from unhealthy attentional deployment and coping strategies comprising the cognitive 
attentional syndrome (CAS), theorised to be an important maintaining factor in depression.
12
 
The CAS includes rumination and worry thought processes, a pattern of focussing attention 
on threat, and use of unhelpful coping strategies that inadvertently extend rather than stop 
negative thinking. These strategies involve cognitive, emotional and behavioural avoidance 
including substance use or bingeing to avoid uncomfortable emotion. A key constituent of 
MCT is the Attention Training Technique (ATT
13
) which is based, in part, on knowledge of 
the executive dysfunction believed to underlie depression. ATT is an auditory attention task 
involving practice of selective and divided attention and attention switching. Attention 
control strategies in MCT aim to ameliorate deficits in executive function and attention 
processes by enhancing attentional capacity and cognitive flexibility - this enables 
disengagement from mood-congruent stimuli (in conjunction with Wells’ detached 
mindfulness strategy), thereby alleviating depressive symptomology.
12
  Detached 
mindfulness, one of MCT’s other core strategies has been defined by Wells as  “a state of 
awareness of internal events, without responding to them with sustained evaluation, attempts 
to control or suppress them , or respond to them behaviourally” ().  ATT has been used with 
good effect for depression as a stand-alone treatment  in a single case series
15
 as well as a 
component of  individual
16
 and group MCT.
17
 
There is promising neuropsychological and imaging evidence of the efficacy of a 
cognitive control training program (comprising ATT combined with the adaptive Paced 
Auditory Serial Attention Task) in patients with depression.
11
 Patients receiving cognitive 
control training performed significantly better than the “treatment as usual” group on 
executive function tests following treatment. In a later study, Siegle and colleagues reported 
that CCT was superior to treatment as usual in reducing levels of rumination and service 
utilisation in severely depressed patients.
18




control training program, the effects of ATT cannot be fully delineated, nevertheless those 
findings along with the Papageorgiou & Wells case series, suggest that ATT may be 
beneficial in improving aspects of executive function in those with depression.  
Given that MCT has components directly targeting executive function and attention 
deficits whereas CBT does not, MCT might be expected to be more effective in ameliorating 
these deficits. Findings in support of this would be important, as it could mean that MCT may 
allow for a more positive longer term prognosis. Our previous pilot study found that MCT 
and CBT were comparable in improving mood symptoms after 12 weeks of outpatient 
psychotherapy
19
 however post hoc analyses suggested that the disproportionate burden of 
social phobia comorbidity in the MCT group may have disadvantaged the MCT outcome. 
The current study examines the relative impact of CBT versus MCT on executive function 
and attentional processes in this sample. Given MCT includes the ATT, it was hypothesised 
that MCT would produce more rapid changes in cognitive functioning by Week 4 and would 
result in greater overall improvements in executive function and attention by the end of 





Materials and Methods 
Participants 
 Participants were 48 men and women aged 18-65 years with a current primary 
depressive episode, who were able to converse and answer questionnaires in English and 
provide informed consent. Exclusion criteria included bipolar I disorder, schizophrenia, 
current severe substance abuse, severe physical illness, an adequate course of CBT or MCT 
in the past year, or use of psychotropic medication (other than the occasional hypnotic). The 
duration of drug-free status was required to be a minimum of two weeks or five drug half-
lives however none in this sample were prescribed antidepressants within the previous six 
weeks.  A research nurse screened referrals for study inclusion/exclusion criteria and 
potential participants were contacted by the next available therapist and booked for a clinical 
interview, following which informed consent was obtained from eligible participants. This 
study received ethical approval from the Upper South B Regional Ethics Committee, New 
Zealand (URB 09/03/012). 
  
Procedure 
Demographic, clinical and neuropsychological assessments were completed at pre-
treatment (Week 0). Clinician-rated diagnostic assessments of mood, anxiety, substance use 
and global assessment of functioning were conducted using the Structured Clinical Interview 
for the Diagnostic and Statistical Manual of Mental Disorders-IV-TR.20 Clinician ratings of 
current mood severity were made using the 16 item Quick Inventory of Depressive 
Symptomology (QIDS-C
21
) and the Montgomery Asberg Depression Rating Scale.22 Further 
key time points for neuropsychological assessment and ratings of depression severity were at 




Participants received up to 12 sessions of therapy, although a range of 8-15 sessions 
was permitted within the 12 weeks. Sessions were conducted twice a week for the first two 
weeks with the aim of six sessions within the first 4 weeks to maximise early change. Four 
clinical psychologists administered both forms of therapy. CBT was based on the manuals of 
Aaron T Beck and colleagues
23
 and Judith Beck.
24





 and Costas Papageorgiou and Wells.
25
 
In MCT, ATT was introduced within the first two sessions and participants were asked 
to listen to the digital audio of ATT (available from http://www.mct-institute.com/therapist-
resources) twice a day for at least two weeks. ATT practice takes approximately 12 minutes 
and consists of three parts: focussed attention on sounds, rapid attention switching between 
sounds, and finally divided attention whereby the participant listens to a number of different 
sounds simultaneously. Participants self-rate their attentional focus pre and post treatment on 
a -3 (external) to + 3 (internal) Likert scale. Participants were also instructed on using in vivo 
practice without the digital audio by using everyday sounds to practice the task. 
Neuropsychological assessment 
Neuropsychological assessments took approximately 90-120 minutes at weeks 0 and 12 
and approximately 60 minutes at week 4. A broad battery of neuropsychological tests was 
administered but apart from the National Adult Reading Test (NART
26
) included as 
descriptive information, only tests related to our hypotheses regarding attention and executive 
functioning are reported here.  
The Groton Maze Learning Task (GMLT
27
), part of the CogState battery  
(www.cogstate.com), is a measure of executive function and spatial problem solving. 
                                                          
1
 Wells, A. (Unpublished). Metacognitive therapy for depression: therapist guidelines and techniques. Therapist 




Participants are required (through trial and error) to find the hidden pathway between the top 
left corner and the lower right corner of a grid by clicking on one tile at a time but were not 
permitted to move diagonally, click on the same tile twice in succession or move backwards 
along the pathway. A tick or cross showed participants whether their move was right or 
wrong. The primary outcome measure was total number of errors made whilst trying to learn 
the pathway; with a lower score reflecting better performance. 
The Controlled Oral Word Association Test (COWAT
28
) is a test of verbal fluency and is 
used as a measure of executive function. Participants generate as many words as possible, 
beginning with a specific letter, over a one minute period. Different sets of letters were used 
at each time point.  
The Rapid Visual Information Processing Task (RVIP: CANTAB
29
) is used as a measure 
of visual sustained attention. Participants were instructed to detect target sequences of digits 
(e.g., 3-5-7) from numbers 1-9 presented in a pseudo-random sequence. Primary outcome 
measures for the task were mean correct latency (time taken to reach a correct response) and 
the total number of hits. 
Data Analyses 
Statistical procedures were conducted using the Statistical Package for the Social 
Sciences (SPSS), version 22-x for Windows.
30
 Baseline data were analysed using 
independent samples t-tests and chi-squared tests. Univariate analyses of covariance 
(ANCOVA) were used to compare the therapy groups on change in executive function and 
attention measures from baseline to subsequent time points. The dependent variable in the 
analyses was the change in task performance from baseline to Week 4 or baseline to Week 
12, therapy group was the fixed factor and baseline depression severity (QIDS) and baseline 




overall change in the sample as a whole was examined. Effect sizes were calculated for the 
differences in change between the two therapy groups. Pearson’s correlational analyses (two-
tailed) were used to examine the relation between change in cognitive task performance and 
change in depression severity. 
Results 
Of the 48 participants (MCT n = 23, CBT n = 25) recruited for the pilot study, all 
completed neuropsychological testing at pre-treatment, 45 attended week 4 
neuropsychological assessments (with complete data available for 43/45: MCT, n = 21; CBT, 
n = 22); and 33 participants (MCT, n = 16; CBT, n = 18) completed neuropsychological 
assessments at end treatment.  Data were available then for 33/48 (69%) of participants at all 
three time points. At end treatment, three participants were unable to be re-tested for logistic 
reasons - following the Canterbury earthquakes we were unable to access our building (and 
the neuropsychological testing equipment) for a number of weeks.  
Demographic data reported previously in the outcome paper
19
 indicated no 
statistically significant differences between groups for age, marital status, ethnicity or other 
clinical characteristics including psychiatric comorbidity which was high in this sample.  
Lifetime “any “anxiety prevalences were 78% in MCT and 64% in CBT groups (Χ
2 
= 1.2, df 
= 1, p=0.29).  
Insert Table 1 about here 
Data relevant to this study are reported in Table 1. At pre-treatment, key demographic 
or clinical characteristics did not differ between the groups. Descriptive data for the total 




morbid IQ mean was 105 (range 83 - 118), the sample was moderately depressed, the mean 
age of onset was 19.8 years and number of prior depressive episodes was three.   
At baseline, no statistical differences were found between the two groups with respect 
to any of the cognitive tasks (Table 2).  
Insert Table 2 about here 
Neuropsychological changes from baseline to Week 4 
No statistical differences were found between the two groups for any of the 
neuropsychological tasks from baseline to Week 4 (Table 2). For the total sample, there was 
a significant reduction in total errors on the GMLT (F1,41 = 6.97, p= 0.01) and a significant 
increase in the number of hits on the RVIP (F1,42 = 24.11, p < 0.001). 
Neuropsychological changes from baseline to end treatment 
There was a statistically significant difference between the two treatment modalities 
in extent of change on the GMLT from baseline to end treatment (Table 2). The MCT group 
showed a reduction in total errors but the CBT group did not (see Figure 1). Differences 
between the two groups for mean correct latency on the RVIP was at a trend level - latency 
reduced in the MCT group whereas in the CBT group, latency increased at week 12. 
Moderate effect sizes were seen for both the GMLT (ES = 0.77, p = 0.03) and mean correct 
latency on the RVIP (ES = 0.65, p = 0.07) although the latter was just outside significance. 
For the total sample, significant increases were found in the number of words generated on 
the COWAT (F1,32 = 16.30, p <0.001) and the number of hits on the RVIP (F1,32 = 19.83, p 
<0.001) but the groups did not differ. 




Relation between neuropsychological change and change in depression severity 
There were no significant correlations between change in depression severity (QIDS), 
and change in cognitive task performance at Week 4 (correlational coefficient range -0.179 - 





The main findings of the study were as follows. By four weeks, there was little 
change in either group and no significant differences between the therapies in their effect on 
cognitive function. At end treatment however, there was a significantly greater improvement 
in performance on the GMLT (spatial working memory and executive function) in the MCT 
group compared with the CBT group. The effect size of the difference was 0.77. There was 
also a moderate effect size difference in favour of MCT on an attentional task (RVPT 
latency); however, this was only at a trend level. Changes in executive  function and attention 
did not correlate with changes in mood. The outcome of our previously published pilot study 
was that both therapies were effective but did not differ in improving depression severity
19
, 
although the greater comorbidity burden in MCT is likely to have affected those results. 
Considered together, these findings add to previous research suggesting only a limited 




As noted earlier, executive functioning comprises a variety of different 
neuropsychological processes. Pietrzak and colleagues
32
 suggested that the total errors score 
on the GMLT is likely to be a measure of psychomotor speed, working memory and 
attention. Specific targeting of attentional processes in MCT might account for the relatively 
greater improvement on both the GMLT and trend level finding for RVIP tasks in the MCT 
group through improved attentional control, relative to other executive function tests such as 
the COWAT which assess other domains of executive function.  
There is a growing literature examining changes in brain function after therapies such 
as CBT for a range of emotional disorders, with increasing numbers of imaging studies 
detecting improvement after psychotherapy (e.g.
33-35




examined the effects of psychotherapy on neuropsychological functioning in depression. One 
large study (n = 272) of young adults by Bastos and colleagues
36
 reported greater 
improvement on measures of working memory, processing speed and executive function after 
24 months of psychodynamic therapy compared to fluoxetine or a combination of the two 
treatments. This suggests that for those without chronic illness, psychotherapy (even without 
specific cognitive remediation strategies) may improve cognition and to a greater extent than 
medication. 
There is increased interest in the use of cognitive remediation strategies, some of 
which resemble ATT, although many batteries are broader in scope (see Porter et al
37
 
review). These studies suggest a positive effect of these interventions on neuropsychological 
function in patients with lifetime or current depression. As noted earlier though, domains 
such as executive function comprise a number of related but distinguishable domains and the 
changes found tend to be focal changes and related to the specific training interventions 
rather than global neuropsychological benefits.
1, 38
 
These preliminary findings suggest MCT may have an advantage over CBT in 
improving certain aspects of executive function, particularly attention. This finding could be 
seen as being consistent with that of Siegle and colleagues of a specific benefit of a cognitive 
control strategy (including ATT as a component) in improving executive function processes, 
compared to their active “treatment as usual” group.
11
 A recent study found that ATT applied 
to traumatic stress symptoms in a non-clinical population resulted in improved self-reported 
attentional flexibility and improved attentional performance on a neuropsychological test of 
emotional set shifting task compared to a control intervention group.
39
 Together these 
findings could be seen to provide preliminary support for the purported mechanism of action 
in MCT; that is, that attentional training and improving control over thinking is associated 




disengage from the cognitive attentional syndrome. 
12, 39
 This supports other literature 
suggesting a specific action of ATT in increasing attentional flexibility enabling attentional 




As noted earlier, persistent cognitive deficits have been found in those with a history 
of mood disorders even when acute mood symptoms are improved to subthreshold levels. 4 
This combined with the present finding of the independence of mood and neuropsychological 
change suggests that the clinical benefits of cognitive remediation may be in domains other 
than mood. Improved executive functioning and attention control is likely to have positive 
impacts in improved life functioning such as academic or occupational functioning but may 
also benefit interpersonal functioning through reducing rumination and excessive self-
focussed attention. 
There are several limitations to the current study. This between-therapy examination of 
neuropsychological change is a secondary analysis of data from our earlier therapy 
comparison pilot study whose outcome was improved depression severity and which was not 
adequately powered to detect small or moderate effect sizes. The sample size issue was 
exacerbated by the earthquake interruption preventing the last three end assessments being 
conducted. Given previous findings from a larger sample of depressed patients who differed 
from control subjects in performance on similar tasks of 0.5 to 0.7
41
, this pilot study was 
unlikely to give anything more than an estimate of between therapy effect size differences to 
inform the design of a larger study. Despite this, differences were found between MCT and 
CBT. The effect sizes of 0.65 - 0.77  in this study for the RVIP latency and GMLT errors 
respectively suggest that a future study examining neuropsychological functioning should 




Given the exploratory nature of this study, correction was not made for multiple 
comparisons; hence, it is possible that the difference on the GMLT is a chance finding. It 
would have been preferable to use repeated measures analysis of variance design with time as 
a factor.  However, the decision to analyse change to Week 4 and to Week 12 separately took 
into account missing data at each time point due to attrition between 4 and 12 weeks. The 
possibility of selective drop-out of subjects with more or less neuropsychological change has 
the potential to affect the findings on overall change; however, we consider that this is 
unlikely to differ between groups given comparable pre-treatment data and dropout rates. 
Although we were interested in early change, it may have been optimistic to expect to detect 
neuropsychological change by 4 weeks, although this clearly occurs by 12 weeks.  
Neuropsychological functioning was not re-assessed at follow-up so we are unable to assess 
how long those changes persist after the end of treatment. 
 This pilot study has a number of strengths. To our knowledge, this is the first study to 
examine the effects of MCT and CBT on neuropsychological functioning in depressed 
individuals. In addition these findings add to the limited literature on neuropsychological 
change associated with psychotherapy for depression. Participants were free of psychotropic 
medication so medication effects can be ruled out as potential confounders. Furthermore the 
majority of participants were referred to the study via health professionals and therefore are 
likely to reflect individuals found in a true clinical sample. The study provides effect size data 







This exploratory study suggests that independent of changes in depressive severity, 
MCT (which includes ATT) may have an advantage over CBT in improving 
neuropsychological functioning where a high attentional capacity is required. The 
comparable between-therapy improvements for other executive function tasks is not 
unexpected given previous research indicating that specific interventions (such as ATT) tend 
to improve related (focal) executive functions rather than global improvement across other 
domains. However given the central role of attention in underpinning other cognitive 
functioning, targeting attention is clearly a worthwhile objective. These preliminary findings 
of specific benefit of MCT in aspects of neuropsychological functioning (along with the 
earlier suggestion that MCT may have been disadvantaged by comorbidity burden) are 
indications of the urgent need for further research using larger samples stratifying for 
potential confounders. Future research should address longer term neuropsychological 
outcomes as well as how changes on tests of neuropsychological functioning translate to real 
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Table 1. Pre-treatment functioning and psychiatric comorbidity in metacognitive 
therapy (MCT) and cognitive behavior therapy (CBT) groups. 
 








 n=23  n=25    
Demographics     
  
Age (years) 37.2  12.7 35.0  13.0 0.60 0.55 
Gender (Male: Female) 52:48  52:48    
Education (Mean years) 14.6 2.7 14.5  2.6 1.67   0.87 
NART IQ 105.5   6.6 104.5  8.3 0.44 0.66 
       
Clinical       
QIDS  15.3 4.1 15.0 4.5 0.24 0.81 
MADRS 24.7  7.7 22.6  7.2 0.96 0.34 
Age onset of depression 22.5  16.2 17.4  19.1 1.32 0.19 
Prior depressive episodes  4.2 3.7 3.4  2.7 0.80 0.43 
       
 
      
Note: 
a
 T-tests for continuous variables or chi-square for dichotomous variables.  
Abbreviations: Standard deviation (SD);  National Adult Reading Test intelligence quotient (NART IQ); Quick 








Table 2.  Neuropsychological performance at baseline, 4 weeks and end treatment (12 weeks) in metacognitive therapy (MCT) and 
cognitive behavior therapy (CBT) groups.  










         
Groton Maze Learning Task 
 n=21  n =23      
Total errors                           Week 0 49.4 20.9 47.8 18.5     
Week 4 43.3 20.9 44.1 14.8     
Change weeks 0 to 4 -6.1 11.8 -3.7 12.4 1,39 0.34 0.56 0.18 
% change from weeks 0 to 4 -12.3%  -7.7%      
Within therapy ES - Week 0 to 4 0.52   0.30       
 n=16  n=18      
Week 0 49.6 22.8. 48.3 20.3     
Week 12 41.9 17.3 48.3 12.2     
Change weeks 0 to 12 -7.7 10.9 0 14.9 1,30 5.04 0.03 0.77 
% change -15.5%  0%      
Within therapy ES -Week 0 to 12 0.71
 






Table 2 (cont.).  Neuropsychological performance at baseline, 4 weeks and end treatment (12 weeks) in metacognitive therapy 
(MCT) and cognitive behavior therapy (CBT) groups.  










         
Controlled Oral Word Association Task 
 n=22  n =23      
Sum of words                        Week 0 42.6 8.7 41.0 13.2     
Week 4 42.1 10.5 41.4 10.6     
Change weeks 0 to 4 -0.5 5.50   0.4 6.2 1,41 0.16 0.68 0.12 
% change from weeks 0 to 4 -1.2%  1.0%%      
Within therapy ES - Week 0 to 4 0.10  0.06       
 n=16  n=18      
Week 0 41.1 9.4 41.3 14.2     
Week 12 43.9 9.9 47.2 14.6     
Change weeks 0 to 12 2.6 7.3 5.9  5.3 1,30 2.06 0.16 0.49 
% change 6.8%   14.3%      






Table 2 (cont.).  Neuropsychological performance at baseline, 4 weeks and end treatment (12 weeks) in metacognitive therapy 

















Rapid Visual Information Processing 
 n=22  n =22      
Hits                                        Week 0 18.5 4.7 18.4 5.2     
Week 4 21.0 3.7 20.9 4.6     
Change weeks 0 to 4 2.5 3.8 2.5 3.0 1,40 <0.01 0.96 0.01 
% change from weeks 0 to 4 13.5%  13.6%      
Within therapy ES - Week 0 to 4 0.67   0.84       
 n=16  n=18      
Week 0 18.2 4.58 17.4 5.5     
Week 12 21.9 4.56 19.9 6.4     
Change weeks 0 to 12 3.7 3.96 2.5 4.1 1,30 1.07 0.31 0.35 
% change 20.3%  14.4%      
Within therapy ES -Week 0 to 12 0.93
 
  0.60       





Table 2 (cont.).  Neuropsychological performance at baseline, 4 weeks and end treatment (12 weeks) in metacognitive therapy 
(MCT) and cognitive behavior therapy (CBT) groups.  










         
Rapid Visual Information Processing 
 n=22  n =23      
Mean Correct Latency         Week 0 411.9 76.9 407.9 76.9     
Week 4 400.6 63.8 400.2 81.4     
Change weeks 0 to 4 -11.3 68.9 -7.7 69.8 1,40 <0.01 0.97 0.01 
% change from weeks 0 to 4 -2.7%  -1.9%      
Within therapy ES - Week 0 to 4 0.16   0.11       
 n=16  n=18      
Week 0 417.6 77.5 405.5 78.7     
Week 12 381.1 52.4 423.6 119.9     
Change weeks 0 to 12 -36.5 76.2 18.1 81.5 1, 30 3.60 0.07 0.65 
% change -8.7%  4.5%      
Within therapy ES -Week 0 to 12 0.48
 
  0.22      





Figure 1 Changes on the Groton Maze Learning Test following metacognitive therapy 
(MCT) or cognitive behaviour therapy (CBT) for depression 
 
 
 
 
